) UCB announces new data at EADV 2026 supporting earlier use of BIMZELX[®] (bimekizumab) for treating hidradenitis suppurativa ... For further information, contact UCB. ... yvonne.naughton@ucb.com ... email sahar.yazdian@ucb.com ... email laurent.schots@ucb.com.
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with ...
As Chief Medical Officer at UCB, I believe that scientific rigor and patient experience must go hand in hand ... That is what continues to motivate me, and what motivates all of us at UCB ... UCB SA published ...
Ultimately, at UCB we imagine an HS-free world, and we're taking steps to make it a reality." ... UCB SA published this content on September 25, 2026, and is solely responsible for the information contained herein.
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with ...
In March 2026, UCB announced that the Committee for Medicinal Products for Human Use (CHMP) had adopted a positive opinion for the pre-filled pen formulation of zilucoplan (ZILBRYSQ) ... (NASDAQ ... Myasthenia GravisOverview ... UCB Biopharma ... UCB Biopharma ... 1 ... 2.
We're now working closely with 10 groups across Europe, Asia and Australia, and those conversations continue to shape how we think about the condition day-to-day and where UCB may be able to help.
The scholarship program reflects UCB's continued commitment to supporting the MG community beyond medicine by helping reduce the financial burden associated with pursuing higher education and career development ... UCB MG Scholarship ... Rare Diseases, UCB.